Arena Capital Advisors’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Arena Capital Advisors’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-100,000	Closed	-$976K	–	354
2021 Q4	$976K	Hold	100,000	–	–	0.09%	176
2021 Q3	$978K	Hold	100,000	–	–	0.08%	183
2021 Q2	$985K	Buy	+100,000	New	+$984K	0.08%	238

Other funds holding EUCR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

ECU

Eisler Capital (UK) London, United Kingdom $21.7B AUM 0.34% 1-Year Est. Return

Arena Capital Advisors's EUCR Position: Q1 2022 in Review

Arena Capital Advisors sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q1 2022, closing a stake of 100,000 shares — an estimated $976K sold.

Arena Capital Advisors first reported a position in EUCR in Q2 2021 and held it in 3 quarters. The position peaked at $985K in Q2 2021. 39 funds tracked by Wall St. Rank hold EUCR as of Q1 2022.

Arena Capital Advisors reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q1 2022 after selling out during the quarter.
Arena Capital Advisors sold 100,000 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q1 2022, an estimated $976K.
Arena Capital Advisors first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q2 2021 and held it in 3 quarters.
Arena Capital Advisors's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $985K in Q2 2021.
39 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q1 2022.

Based on Arena Capital Advisors's 13F filing for Q1 2022, filed 13 May 2022.